Market Closed -
Nasdaq
01:30:00 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
5.52
USD
|
+5.34%
|
|
+5.54%
|
-14.42%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
721.4
|
848.3
|
266.7
|
272.3
|
305.4
|
-
|
-
|
Enterprise Value (EV)
1 |
555.3
|
805.5
|
-79.1
|
272.3
|
159
|
-26.61
|
105
|
P/E ratio
|
-3.25
x
|
-8.38
x
|
-2.44
x
|
-2.76
x
|
-2.57
x
|
-3.5
x
|
-3.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,678
x
|
643
x
|
13.9
x
|
7.97
x
|
12.9
x
|
8.97
x
|
8.07
x
|
EV / Revenue
|
1,291
x
|
611
x
|
-4.11
x
|
7.97
x
|
6.7
x
|
-0.78
x
|
2.77
x
|
EV / EBITDA
|
-8.26
x
|
-8.26
x
|
0.69
x
|
-2.61
x
|
-1.22
x
|
0.21
x
|
-0.64
x
|
EV / FCF
|
-
|
-15
x
|
-0.41
x
|
-
|
-1.41
x
|
0.21
x
|
-0.92
x
|
FCF Yield
|
-
|
-6.65%
|
-243%
|
-
|
-71.1%
|
470%
|
-109%
|
Price to Book
|
5.1
x
|
9.75
x
|
2,363
x
|
-
|
-30.7
x
|
-3.52
x
|
-
|
Nbr of stocks (in thousands)
|
35,591
|
37,093
|
41,802
|
42,217
|
55,329
|
-
|
-
|
Reference price
2 |
20.27
|
22.87
|
6.380
|
6.450
|
5.520
|
5.520
|
5.520
|
Announcement Date
|
18/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.43
|
1.319
|
19.23
|
34.16
|
23.72
|
34.03
|
37.86
|
EBITDA
1 |
-
|
-67.2
|
-97.51
|
-113.8
|
-104.5
|
-130.7
|
-125.9
|
-164
|
EBIT
1 |
-
|
-68.53
|
-100.7
|
-117.1
|
-107.9
|
-119.3
|
-122.4
|
-124.5
|
Operating Margin
|
-
|
-15,937.44%
|
-7,637.15%
|
-609.2%
|
-315.93%
|
-502.86%
|
-359.54%
|
-328.8%
|
Earnings before Tax (EBT)
1 |
-
|
-68.8
|
-101.3
|
-108.9
|
-94.2
|
-108
|
-104.9
|
-114.2
|
Net income
1 |
-51.13
|
-68.8
|
-101.3
|
-108.9
|
-98.43
|
-108.2
|
-110
|
-115.6
|
Net margin
|
-
|
-16,000%
|
-7,681.58%
|
-566.27%
|
-288.17%
|
-456.19%
|
-323.23%
|
-305.49%
|
EPS
2 |
-1.410
|
-6.230
|
-2.730
|
-2.620
|
-2.340
|
-2.145
|
-1.578
|
-1.450
|
Free Cash Flow
1 |
-
|
-
|
-53.56
|
192.4
|
-
|
-113
|
-125.1
|
-114.5
|
FCF margin
|
-
|
-
|
-4,060.88%
|
1,000.63%
|
-
|
-476.57%
|
-367.55%
|
-302.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/10/20
|
18/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.713
|
3.92
|
4.49
|
6.634
|
4.184
|
5.309
|
5.599
|
17.48
|
5.769
|
5.05
|
6.726
|
6.814
|
7.574
|
9.5
|
9.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.08
|
-27.8
|
-29.19
|
-28.26
|
-31.89
|
-33.32
|
-32.05
|
-17.08
|
-25.46
|
-28.19
|
-30.17
|
-30.49
|
-30.17
|
-
|
-
|
Operating Margin
|
-3,938.57%
|
-709.29%
|
-650.07%
|
-425.97%
|
-762.09%
|
-627.56%
|
-572.42%
|
-97.73%
|
-441.29%
|
-558.3%
|
-448.62%
|
-447.48%
|
-398.33%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-29.14
|
-26.91
|
-27.31
|
-25.77
|
-28.89
|
-29.93
|
-28.54
|
-13.61
|
-22.12
|
-25.02
|
-22.07
|
-22.34
|
-21.46
|
-
|
-
|
Net income
1 |
-29.14
|
-26.91
|
-27.31
|
-25.77
|
-28.89
|
-30.49
|
-29.49
|
-14.34
|
-24.11
|
-25.02
|
-24.23
|
-25.11
|
-25.43
|
-
|
-
|
Net margin
|
-4,087.38%
|
-686.58%
|
-608.31%
|
-388.44%
|
-690.39%
|
-574.27%
|
-526.65%
|
-82.07%
|
-417.85%
|
-495.37%
|
-360.3%
|
-368.43%
|
-335.76%
|
-
|
-
|
EPS
2 |
-0.7700
|
-0.6500
|
-0.6600
|
-0.6200
|
-0.6900
|
-0.7300
|
-0.7000
|
-0.3400
|
-0.5700
|
-0.5900
|
-0.6550
|
-0.5000
|
-0.4575
|
-0.3600
|
-0.3700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/22
|
09/05/22
|
09/08/22
|
08/11/22
|
09/03/23
|
08/05/23
|
04/08/23
|
02/11/23
|
07/03/24
|
06/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
166
|
42.8
|
346
|
-
|
146
|
332
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-53.6
|
192
|
-
|
-113
|
-125
|
-115
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-83.4%
|
-225%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
3.970
|
2.350
|
0
|
-
|
-0.1800
|
-1.570
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
3.31
|
1.21
|
-
|
4.41
|
4.85
|
3.92
|
Capex / Sales
|
-
|
-
|
251.18%
|
6.29%
|
-
|
18.59%
|
14.25%
|
10.35%
|
Announcement Date
|
02/10/20
|
18/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
5.24
USD Average target price
11.67
USD Spread / Average Target +122.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.42% | 290M | | +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|